Friday 6 November 2026 Export SYK’s income statement to Excel — free account

Stryker Corporation

Stryker Corporation’s revenue for fiscal 2025 (year ended December 2025) was $25.1 billion, up 11.2% from fiscal 2024.

Revenue: +7.64%
EPS: −12.4%
Free cash flow: −19.4%
Total debt: −10.0%

Quarter to September 2026, against a year earlier

325.11 9.97 −2.98%

Follow SYK

Alert me

Market cap: $127.6B
P/E: 35.3×
Fwd P/E: 24.6×
Dividend yield: 1.05%
F-score: 5/9
Altman Z: 4.81
Beneish M: −2.62
Dividend safety: 82/100

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Stryker Corporation (SYK) revenue by segment, product and region

Where the money comes from and where it goes

Fiscal 2025: revenue by regions, and margins
United States	19,006	75.67%
Europe, Middle East, Africa	3,181	12.67%
Asia Pacific	2,164	8.62%
Other foreign countries	765	3.05%
Gross margin		63.96%
Operating margin		19.47%
Pre-tax margin		17.97%

Revenue by segment $m

Line	FY2021	FY2020	FY2019	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009	FY2008
MedSurg and Neurotechnology:	9,538 55.75%	8,345 58.15%	8,475 56.94%	—	—	—	—	—	—	—	—
Orthopaedics:	7,570 44.25%	6,006 41.85%	6,409 43.06%	—	—	—	—	—	—	—	—
Reconstructive	—	—	—	4,223 42.46%	4,153 42.93%	3,949 43.78%	3,823 44.16%	3,710 44.66%	3,549 48.48%	3,384 50.33%	—
MedSurg	—	—	—	3,895 39.16%	3,781 39.08%	3,414 37.85%	3,265 37.72%	3,160 38.04%	2,803 38.29%	2,427 36.10%	2,751 40.94%
Neurotechnology And Spine	—	—	—	1,828 18.38%	1,741 17.99%	1,658 18.38%	1,569 18.12%	1,437 17.30%	968 13.22%	912 13.57%	—
Other European countries	—	—	—	—	—	—	—	—	—	1,234 18.35%	—
Ireland	—	—	—	—	—	—	—	—	—	20 0.30%	—
Orthopaedic Implants	—	—	—	—	—	—	—	—	—	—	3,968 59.06%
Eliminations	—	—	—	—	—	—	—	—	—	(1,254) (18.65%)	—
Revenue	17,108	14,351	14,884	9,946	9,675	9,021	8,657	8,307	7,320	6,723	6,718

Operating income by segment $m, and margin

	FY2021	FY2020	FY2019	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009	FY2008
MedSurg and Neurotechnology:	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Orthopaedics:	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Reconstructive	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
MedSurg	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Neurotechnology And Spine	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Corporate and Other	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Operating Segments	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Other Businesses	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Corporate and other	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Operating income	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

Revenue by region $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2008
United States	19,006 75.67%	16,943 74.99%	15,257 74.43%	13,638 73.92%	12,321 72.02%	10,455 72.85%	10,957 73.62%	9,848 72.41%	9,059 72.80%	8,230 72.67%	7,116 71.55%	6,558 67.78%	5,984 66.33%	5,658 65.36%	5,269 63.43%	4,793 65.48%	4,282 63.74%
Europe, Middle East, Africa	3,181 12.67%	2,897 12.82%	2,618 12.77%	2,348 12.73%	2,299 13.44%	1,818 12.67%	1,888 12.68%	1,793 13.18%	1,567 12.59%	1,437 12.69%	1,267 12.74%	1,371 14.17%	1,316 14.59%	1,266 14.62%	1,382 16.64%	1,228 16.78%	1,313 19.55%
Asia Pacific	2,164 8.62%	2,020 8.94%	1,946 9.49%	1,885 10.22%	1,973 11.53%	1,630 11.36%	1,617 10.86%	1,532 11.26%	1,413 11.35%	1,325 11.70%	1,251 12.58%	1,368 14.14%	1,319 14.62%	1,336 15.43%	1,285 15.47%	991 13.54%	—
Other foreign countries	765 3.05%	735 3.25%	677 3.30%	578 3.13%	515 3.01%	448 3.12%	422 2.84%	428 3.15%	405 3.25%	333 2.94%	312 3.14%	378 3.91%	402 4.46%	397 4.59%	371 4.47%	308 4.21%	1,123 16.71%
International	6,110	5,652	5,241	4,811	4,787	3,896	3,927	3,753	3,385	3,095	—	—	—	—	—	—	—
Revenue	25,116	22,595	20,498	18,449	17,108	14,351	14,884	13,601	12,444	11,325	9,946	9,675	9,021	8,657	8,307	7,320	6,718

Operating figures as reported in each quarter’s results release or filing

Figure	Quarter	Latest	A year before	Change
Higher prices	Q1 FY2026	0.30%	0.70%	—
Increased unit volume	Q2 FY2026	9.00%	9.70%	—

	Q2 FY2026	Q1 FY2026	Q4 FY2025	Q3 FY2025	Q2 FY2025	Q1 FY2025	Q4 FY2024	Q3 FY2024	Q2 FY2024	Q1 FY2024	Q4 FY2023	Q3 FY2023
Higher prices	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Increased unit volume	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.